Literature DB >> 18696266

Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit.

Susanne Muehlschlegel1, John R Sims.   

Abstract

Calcium plays a central role in neuronal function and injury. Dantrolene, an inhibitor of the ryanodine receptor, inhibits intracellular calcium release from the sarco-endoplasmic reticulum. We review the available data of dantrolene as a potential neuroprotective agent and briefly summarize its other pharmacologic effects that may have potential applications for patients in the neurointensive care unit (NICU). Areas with the need for continued research are identified.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18696266      PMCID: PMC2702250          DOI: 10.1007/s12028-008-9133-4

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.532


  112 in total

1.  Protection of ischemic rat heart by dantrolene, an antagonist of the sarcoplasmic reticulum calcium release channel.

Authors:  G Yu; R Zucchi; S Ronca-Testoni; G Ronca
Journal:  Basic Res Cardiol       Date:  2000-04       Impact factor: 17.165

2.  Dantrolene sodium and hepatic injury.

Authors:  C H Chan
Journal:  Neurology       Date:  1990-09       Impact factor: 9.910

3.  HIV-1 coat protein gp120-induced increases in levels of intrasynaptosomal calcium.

Authors:  A Nath; R A Padua; J D Geiger
Journal:  Brain Res       Date:  1995-04-24       Impact factor: 3.252

4.  L-type Ca2+ channel blockers attenuate electrical changes and Ca2+ rise induced by oxygen/glucose deprivation in cortical neurons.

Authors:  A Pisani; P Calabresi; A Tozzi; V D'Angelo; G Bernardi
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

5.  Role of RyRs and IP3 receptors after traumatic injury to spinal cord white matter.

Authors:  W E Thorell; L G Leibrock; S K Agrawal
Journal:  J Neurotrauma       Date:  2002-03       Impact factor: 5.269

6.  Protective effect of dantrolene sodium on carbon tetrachloride induced liver injury in the rat.

Authors:  F Yamagishi; T Komoda; K Ohnishi; S Itoh
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1993-11

7.  Dantrolene protects against ischemic, delayed neuronal death in gerbil brain.

Authors:  L Zhang; Y Andou; S Masuda; A Mitani; K Kataoka
Journal:  Neurosci Lett       Date:  1993-08-06       Impact factor: 3.046

8.  Kainic acid-induced seizures and brain damage in the rat: role of calcium homeostasis.

Authors:  M Berg; T Bruhn; A Frandsen; A Schousboe; N H Diemer
Journal:  J Neurosci Res       Date:  1995-04-01       Impact factor: 4.164

9.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia.

Authors:  D H MacLennan; C Duff; F Zorzato; J Fujii; M Phillips; R G Korneluk; W Frodis; B A Britt; R G Worton
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962

10.  Fever in acute stroke worsens prognosis. A prospective study.

Authors:  G Azzimondi; L Bassein; F Nonino; L Fiorani; L Vignatelli; G Re; R D'Alessandro
Journal:  Stroke       Date:  1995-11       Impact factor: 7.914

View more
  33 in total

1.  Effects of dantrolene on apoptosis and immunohistochemical expression of NeuN in the spinal cord after traumatic injury in rats.

Authors:  Bruno Benetti Junta Torres; Fátima Maria Caetano Caldeira; Mardelene Geísa Gomes; Rogéria Serakides; Aline de Marco Viott; Angélica Cavalheiro Bertagnolli; Fabíola Bono Fukushima; Karen Maciel de Oliveira; Marcus Vinícius Gomes; Eliane Gonçalves de Melo
Journal:  Int J Exp Pathol       Date:  2010-10-05       Impact factor: 1.925

2.  Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury.

Authors:  Saef Izzy; Susanne Muehlschlegel
Journal:  Curr Treat Options Neurol       Date:  2014-01       Impact factor: 3.598

Review 3.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

4.  Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease.

Authors:  Bénédicte Oulès; Dolores Del Prete; Barbara Greco; Xuexin Zhang; Inger Lauritzen; Jean Sevalle; Sebastien Moreno; Patrizia Paterlini-Bréchot; Mohamed Trebak; Frédéric Checler; Fabio Benfenati; Mounia Chami
Journal:  J Neurosci       Date:  2012-08-22       Impact factor: 6.167

5.  Dantrolene inhibits the calcium plateau and prevents the development of spontaneous recurrent epileptiform discharges following in vitro status epilepticus.

Authors:  Nisha Nagarkatti; Laxmikant S Deshpande; Dawn S Carter; Robert J DeLorenzo
Journal:  Eur J Neurosci       Date:  2010-06-28       Impact factor: 3.386

6.  Tau pathology-mediated presynaptic dysfunction.

Authors:  H Moreno; G Morfini; L Buitrago; G Ujlaki; S Choi; E Yu; J E Moreira; J Avila; S T Brady; H Pant; M Sugimori; R R Llinás
Journal:  Neuroscience       Date:  2016-03-21       Impact factor: 3.590

Review 7.  Approaches to Optimizing Dantrolene Neuroprotection for the Treatment of Alzheimer's Disease.

Authors:  Matan B Abou; Liang Sun; Huafeng Wei
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

8.  Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.

Authors:  Salvatore Salomone; Guray Soydan; Michael A Moskowitz; John Randall Sims
Journal:  Neurocrit Care       Date:  2008-10-16       Impact factor: 3.210

9.  Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.

Authors:  Benjamin Liou; Yanyan Peng; Ronghua Li; Venette Inskeep; Wujuan Zhang; Brian Quinn; Nupur Dasgupta; Rachel Blackwood; Kenneth D R Setchell; Sheila Fleming; Gregory A Grabowski; John Marshall; Ying Sun
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

10.  Could dantrolene be explored as a repurposed drug to treat COVID-19 patients by restoring intracellular calcium homeostasis?

Authors:  B Jiang; S Liang; G Liang; H Wei
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-10       Impact factor: 3.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.